Overview

Effects of Intravenous (IV) Citalopram Hydrochloride During Transcranial Magnetic Stimulation in Major Depressive Disorder (MDD)

Status:
Active, not recruiting

Trial end date:
2022-04-24

Target enrollment:

Participant gender:

Summary

This study will recruit 30 subjects diagnosed with Major Depressive Disorder (MDD). Subjects will be recieve one infusion treatment of citalopram or placebo and 10 treatments of a form of transcranial magnetic stimulation, theta burst stimulation (TBS). Subjects will also undergo brain scans, quantitative electroencephalography (qEEG) brain activity recordings, and mood surveys. Study activities will be performed over the course of 4 weeks.

Phase:

Early Phase 1

Details

Lead Sponsor:

University of California, Los Angeles

Treatments:

Citalopram